Szutowicz-Zielinska, E., Konopa, K., Kowalczyk, A., Suszko-Kazarnowicz, M., Duchnowska, R., Szczesna, A., . . . Dziadziuszko, R. (2016). An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. Oncotarget.
Chicago Style CitationSzutowicz-Zielinska, Ewa, et al. "An Open Label Phase II Study Evaluating First-line EGFR Tyrosine Kinase Inhibitor Erlotinib in Non-small Cell Lung Cancer Patients With Tumors Showing High EGFR Gene Copy Number." Oncotarget 2016.
Cita MLASzutowicz-Zielinska, Ewa, et al. "An Open Label Phase II Study Evaluating First-line EGFR Tyrosine Kinase Inhibitor Erlotinib in Non-small Cell Lung Cancer Patients With Tumors Showing High EGFR Gene Copy Number." Oncotarget 2016.